Trial · NCT07896642
Registered outcomes26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 26
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Supraclavicular Skin Temperature (Tscv) | At baseline for all participants | Supraclavicular skin temperature (Tscv) will be measured with a FLIR E5 Pro infrared thermal imaging camera after a standardized mild cold exposure protocol (hand immersion in cold water for 5 minutes). Mean temperatures of the right and left supraclavicular regions of interest will be averaged to obtain a single Tscv value, reported in degrees Celsius (°C), as an indicator of brown adipose tissue activity. |
| Primary | Serum Uncoupling Protein 1 (UCP-1) Level | At baseline for all participants | Serum UCP-1 concentration will be measured using a commercial human sandwich ELISA kit as a biochemical marker of brown adipose tissue activity and thermogenesis, and reported in ng/L. |
| Secondary | Relative Supraclavicular Skin Temperature (Trel) | At baseline for all participants | Relative supraclavicular skin temperature (Trel) will be calculated as the difference between Tscv and the reference skin temperature (Tref) measured over the sternal region (corpus sterni), a region without brown adipose tissue, on the same thermal image (Trel = Tscv - Tref). Values from the right and left sides will be averaged to obtain a single Trel value, reported in degrees Celsius (°C). |
| Secondary | Body Temperature | At baseline for all participants | Body temperature will be measured and reported in degrees Celsius (°C). |
| Secondary | Body Weight | At baseline for all participants | Body weight will be measured and reported in kilograms (kg). |
| Secondary | Waist Circumference | At baseline for all participants | Waist circumference will be measured and reported in centimeters (cm). |
| Secondary | Body Mass Index (BMI) | At baseline for all participants | BMI will be calculated as body weight in kilograms divided by the square of height in meters and reported in kg/m². |
| Secondary | Body Fat Percentage | At baseline for all participants | Body fat percentage will be measured using a household-type Tanita body composition scale (bioelectrical impedance) and reported as a percentage (%) of total body weight. |
| Secondary | Basal Metabolic Rate | At baseline for all participants | Basal metabolic rate will be estimated using a household-type Tanita body composition scale (bioelectrical impedance) and reported in kilocalories per day (kcal/day). |
| Secondary | Systolic Blood Pressure | At baseline for all participants | Systolic blood pressure will be measured and reported in millimeters of mercury (mmHg). |
| Secondary | Diastolic Blood Pressure | At baseline for all participants | Diastolic blood pressure will be measured and reported in millimeters of mercury (mmHg). |
| Secondary | Serum Follicle-Stimulating Hormone (FSH) | At baseline for all participants | Serum FSH concentration will be measured and reported in mIU/mL. |
| Secondary | Serum Luteinizing Hormone (LH) | At baseline for all participants | Serum LH concentration will be measured and reported in mIU/mL. |
| Secondary | LH/FSH Ratio | At baseline for all participants | The LH/FSH ratio will be calculated by dividing serum LH (mIU/mL) by serum FSH (mIU/mL) and reported as a unitless ratio. |
| Secondary | Serum Estradiol (E2) | At baseline for all participants | Serum estradiol concentration will be measured and reported in pg/mL. |
| Secondary | Serum Thyroid-Stimulating Hormone (TSH) | At baseline for all participants. | Serum TSH concentration will be measured and reported in µIU/mL. |
| Secondary | Serum Dehydroepiandrosterone Sulfate (DHEA-S) | At baseline for all participants | Serum DHEA-S concentration will be measured and reported in µg/dL. |
| Secondary | Serum Total Testosterone | At baseline for all participants | Serum total testosterone concentration will be measured and reported in ng/mL. |
| Secondary | Modified Ferriman-Gallwey (mFG) Hirsutism Score | At baseline for all participants | Hirsutism will be assessed using the modified Ferriman-Gallwey (mFG) scoring system, in which nine androgen-sensitive body areas are each scored from 0 (no terminal hair) to 4 (maximal terminal hair growth). Item scores will be summed to obtain a total score (units on a scale). The minimum score is 0 and the maximum score is 36; higher scores indicate more severe hirsutism (worse outcome). |
| Secondary | Fasting Serum Glucose | At baseline for all participants | Fasting serum glucose will be measured after an overnight fast and reported in mg/dL. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07896642/registered